Form SC 13G Sarepta Therapeutics, Filed by: Point72 Asset Management, L.P.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil hovers near $100 on rising Middle East tensions
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Point72 Asset Management, L.P. Raises Stake in Sarepta Therapeutics (SRPT) to 5.3%
May 1, 2015 4:21 PM EDTIn a 13G filing on Sarepta Therapeutics (NASDAQ: SRPT), hedge fund Point72 Asset Management, L.P. disclosed a 5.3%, or 2,193,600 share, stake in the company. This is up 697.09% from the 275,200 shares held at the end of the latest quarter ending Dec. 31, 2015.
For more notable holders of Sarepta Therapeutics stock click here.
... More